Suppr超能文献

直接肾素抑制与 AT1R 阻断对转基因 Ren2 大鼠肾小球滤过屏障损伤的比较作用。

Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat.

机构信息

Department of Internal Medicine, University of Missouri-Columbia School of Medicine, Columbia, Missouri 65212, USA.

出版信息

Am J Physiol Renal Physiol. 2010 Mar;298(3):F655-61. doi: 10.1152/ajprenal.00373.2009. Epub 2009 Dec 9.

Abstract

Renin-angiotensin system (RAS) activation contributes to kidney injury through oxidative stress. Renin is the rate-limiting step in angiotensin (ANG II) generation. Recent work suggests renin inhibition improves proteinuria comparable to ANG type 1 receptor (AT1R) blockade (ARB). Thereby, we investigated the relative impact of treatment with a renin inhibitor vs. an ARB on renal oxidative stress and associated glomerular structural and functional changes in the transgenic Ren2 rat, which manifests hypertension, albuminuria, and increased tissue RAS activity. Young Ren2 and age-matched Sprague-Dawley (SD) controls (age 6-9 wk) were treated with a renin inhibitor (aliskiren), an ARB (irbesartan), or vehicle for 21 days. Ren2 rats exhibited increases in systolic pressure (SBP), albuminuria, and renal 3-nitrotyrosine content as well as ultrastructural podocyte foot-process effacement and diminution of the podocyte-specific protein nephrin. Structural and functional alterations were accompanied by increased renal cortical ANG II, AT1R, as well as NADPH oxidase subunit (Nox2) expression compared with SD controls. Abnormalities were attenuated to a similar extent with both aliskiren and irbesartan treatment. Despite the fact the dose of irbesartan used caused a greater reduction in SBP than aliskerin treatment (P < 0.05), the effects on proteinuria, nephrin, and oxidative stress were similar between the two treatments. Our results highlight both the importance of pressor-related reductions on podocyte integrity and albuminuria as well as RAS-mediated oxidant stress largely comparable between ARB and renin inhibition treatment.

摘要

肾素-血管紧张素系统(RAS)的激活通过氧化应激导致肾脏损伤。肾素是血管紧张素(ANG II)生成的限速步骤。最近的研究表明,肾素抑制可改善蛋白尿,与血管紧张素 1 型受体(AT1R)阻断剂(ARB)相当。因此,我们研究了肾素抑制剂与 ARB 治疗对转基因 Ren2 大鼠肾脏氧化应激及相关肾小球结构和功能变化的相对影响,该大鼠表现为高血压、白蛋白尿和组织 RAS 活性增加。年轻的 Ren2 和年龄匹配的 Sprague-Dawley(SD)对照(6-9 周龄)用肾素抑制剂(阿利克仑)、ARB(厄贝沙坦)或载体治疗 21 天。Ren2 大鼠的收缩压(SBP)、白蛋白尿和肾脏 3-硝基酪氨酸含量增加,以及足细胞突起融合和足细胞特异性蛋白nephrin 减少。与 SD 对照组相比,结构和功能改变伴随着肾皮质 ANG II、AT1R 以及 NADPH 氧化酶亚基(Nox2)表达增加。阿利克仑和厄贝沙坦治疗均可使这些异常减轻到相似程度。尽管厄贝沙坦的剂量导致 SBP 降低幅度大于阿利克仑(P < 0.05),但两种治疗方法对蛋白尿、nephrin 和氧化应激的影响相似。我们的结果强调了降压相关的足细胞完整性和白蛋白尿的重要性,以及 ARB 和肾素抑制治疗中 RAS 介导的氧化应激之间的相似性。

相似文献

1
Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat.
Am J Physiol Renal Physiol. 2010 Mar;298(3):F655-61. doi: 10.1152/ajprenal.00373.2009. Epub 2009 Dec 9.
2
Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat.
Am J Physiol Endocrinol Metab. 2008 Jul;295(1):E103-9. doi: 10.1152/ajpendo.00752.2007. Epub 2008 May 6.
4
Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat.
Am J Physiol Renal Physiol. 2006 Dec;291(6):F1308-14. doi: 10.1152/ajprenal.00167.2006. Epub 2006 Jun 20.
5
Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat.
Am J Physiol Renal Physiol. 2009 May;296(5):F1013-22. doi: 10.1152/ajprenal.90646.2008. Epub 2009 Mar 4.
6
Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling.
Metabolism. 2013 Jun;62(6):861-72. doi: 10.1016/j.metabol.2012.12.012. Epub 2013 Jan 24.
9
Renin-angiotensin blockade resets podocyte epigenome through Kruppel-like Factor 4 and attenuates proteinuria.
Kidney Int. 2015 Oct;88(4):745-53. doi: 10.1038/ki.2015.178. Epub 2015 Jun 24.
10
Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment.
Hypertension. 2008 Feb;51(2):474-80. doi: 10.1161/HYPERTENSIONAHA.107.102467. Epub 2008 Jan 2.

引用本文的文献

2
Treatment of nephrotic syndrome: going beyond immunosuppressive therapy.
Pediatr Nephrol. 2020 Apr;35(4):569-579. doi: 10.1007/s00467-019-04225-7. Epub 2019 Mar 23.
3
The effect of aliskiren on the renal dysfunction following unilateral ureteral obstruction in the rat.
Int J Physiol Pathophysiol Pharmacol. 2016 Aug 5;8(2):70-7. eCollection 2016.
4
The podocyte as a direct target for treatment of glomerular disease?
Am J Physiol Renal Physiol. 2016 Jul 1;311(1):F46-51. doi: 10.1152/ajprenal.00184.2016. Epub 2016 Apr 20.
5
Can Aliskiren be Considered as a New Novel Drug for Hypertension?
Cureus. 2015 Nov 4;7(11):e375. doi: 10.7759/cureus.375.
6
Olmesartan attenuates tacrolimus-induced biochemical and ultrastructural changes in rat kidney tissue.
Biomed Res Int. 2014;2014:607246. doi: 10.1155/2014/607246. Epub 2014 May 28.
7
Role of NADPH oxidase-mediated reactive oxygen species in podocyte injury.
Biomed Res Int. 2013;2013:839761. doi: 10.1155/2013/839761. Epub 2013 Nov 11.
8
Central angiotensin-(1-7) improves vagal function independent of blood pressure in hypertensive (mRen2)27 rats.
Hypertension. 2012 Nov;60(5):1257-65. doi: 10.1161/HYPERTENSIONAHA.112.196782. Epub 2012 Oct 8.
9
Mineralocorticoid Receptor Blocker Protects against Podocyte-Dependent Glomerulosclerosis.
Nephron Extra. 2012 Jan;2(1):17-26. doi: 10.1159/000334961. Epub 2012 Jan 31.

本文引用的文献

2
Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors?
Kidney Int. 2009 Jul;76(1):23-31. doi: 10.1038/ki.2009.105. Epub 2009 Apr 15.
4
Low aerobic capacity and high-fat diet contribute to oxidative stress and IRS-1 degradation in the kidney.
Am J Nephrol. 2009;30(2):112-9. doi: 10.1159/000204362. Epub 2009 Feb 20.
5
Redox control of renal function and hypertension.
Antioxid Redox Signal. 2008 Dec;10(12):2047-89. doi: 10.1089/ars.2008.2034.
6
Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat.
Endocrinology. 2008 Nov;149(11):5643-53. doi: 10.1210/en.2008-0070. Epub 2008 Jul 24.
7
Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.
Hypertension. 2008 Sep;52(3):563-72. doi: 10.1161/HYPERTENSIONAHA.108.111120. Epub 2008 Jul 21.
8
Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
Circulation. 2008 Jun 24;117(25):3199-205. doi: 10.1161/CIRCULATIONAHA.108.767202. Epub 2008 Jun 16.
9
Aliskiren combined with losartan in type 2 diabetes and nephropathy.
N Engl J Med. 2008 Jun 5;358(23):2433-46. doi: 10.1056/NEJMoa0708379.
10
Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats.
Hypertension. 2008 Jul;52(1):130-6. doi: 10.1161/HYPERTENSIONAHA.107.108845. Epub 2008 May 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验